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Abstract
Background: EUS-guided FNA can help diagnose and differentiate between various pancreatic and other lesions.
The aim of this study was to compare approaches among involved/relevant physicians to the controversies
surrounding the use of FNA in EUS.
Methods: A five-case survey was developed, piloted, and validated. It was collected from a total of 101 physicians,
who were all either gastroenterologists (GIs), surgeons or oncologists. The survey compared the management
strategies chosen by members of these relevant disciplines regarding EUS-guided FNA.
Results: For CT operable T2NOM0 pancreatic tumors the research demonstrated variance as to whether to
undertake EUS-guided FNA, at p < 0.05. For inoperable pancreatic tumors 66.7% of oncologists, 62.2% of surgeons
and 79.1% of GIs opted for FNA (p < 0.05). For cystic pancreatic lesions, oncologists were more likely to send
patients to surgery without FNA. For stable simple pancreatic cysts (23 mm), most physicians (66.67%) did not
recommend FNA. For a submucosal gastric 19 mm lesion, 63.2% of surgeons recommended FNA, vs. 90.0% of
oncologists (p < 0.05).
Conclusions: Controversies as to ideal application of EUS-FNA persist. Optimal guidelines should reflect the needs
and concerns of the multidisciplinary team who treat patients who need EUS-FNA. Multi-specialty meetings
assembled to manage patients with these disorders may be enlightening and may help develop consensus.
Background
Pancreatic cancer (PCA) is the fourth leading cause of
cancer-related death in the United States [1]. Although
relatively common, it is considered challengingly diffi-
cult both to diagnose early and to treat. Pancreatic solid
tumors are often malignant, with adenocarcinoma being
the most prevalent histological form. However, about
10% of the tumors are of various other histologies, with
different natural history and management considerations
[2]. Currently, the only option for a cure for PCA
patients begins with surgical extirpation of the tumor.
Yet, even with surgery the prognosis is often guarded
or even poor. The less common pancreatic malignancies,
mainly neuroendocrine cancers and lymphomas, have
considerably better prognoses.
Several methods are used for detecting and diagnosing
pancreatic lesions. Each method has its advantages and
disadvantages, including costs, availability, local exper-
tise, operator-dependency, and tradeoffs of accuracy
rates for morbidity. Understaging results regarding the
resectability of pancreatic tumors leads to undertaking
futile and dangerous operations [3,4]. Overstaging of a
pancreatic tumor by any of these methods (all of which
have some proven fallibility) would lead to a potentially
operable lesion being treated with only palliative mea-
sures, essentially ‘giving up’ on rescuing the patient’s
life, or lead to unnecessary neoadjuvant therapies.
A related issue is that EUS-guided FNA can evaluate
gastrointestinal tract submucosal lesions very well, with
a near 100% accuracy. A gastrointestinal stromal tumor
(GIST) is one of the important histologic/cytologic diag-
noses of submucosal lesions [5].
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tance for further management decisions. Those GISTs
staining positively for the c-KIT mutation often respond
well to imatinib [6].
There are some controversies regarding the indica-
tions for performing EUS-guided FNA. These are several
of the key unanswered questions:
- Is it necessary to obtain a tissue diagnosis of a pan-
creatic mass which appears operable and has malig-
nant features according to a CT scan or EUS?
- Should one order EUS-guided FNA of a CT-inop-
erable tumor, prior to initiating chemotherapy or
radiation therapy?
- Regarding a stable pancreatic cyst, is periodic radi-
ological follow-up sufficient, or is there a need for
sampling the lesion for the existence of such indica-
tors as CEA, amylase and lipase.
- When is EUS-guided FNA sampling of a submuco-
sal GI tract lesion indicated? The leading principle
in determining an indication for performing any
medical test is whether or not the information gath-
ered by this method is likely to change the recom-
mended treatment plans, and thus improve the
patient’s prognosis.
As access to EUS becomes more widespread, EUS-
guided FNA of pancreatic and GI submucosal lesions
is becoming increasingly common. In Israel, there has
been a rise from fourteen medical centers performing
3700 EUS procedures in 2001 to twenty centers per-
forming 5000 procedures annually, three years later
[7].
To date, clear and accepted indications with unison
among the relevant physicians regarding when to per-
form EUS-guided FNA and when to refrain from FNA,
are lacking. One landmark study showed that only
about 50% of gastroenterologists who treat patients with
pancreatic cystic lesions were aware of the existence of
such guidelines, and many did not accept the current
consensus guidelines [8].
While it presents too small a survey to establish defi-
nitive guidelines, the present work humbly aims to for-
mulate a milestone in the final mission of creating a
consensus by surveying specialists from the various rele-
vant fields, as to the indications of EUS-guided FNA.
Methods
The survey
Based on the areas of controversy mentioned above, a
questionnaire was developed by expert consensus with a
pilot for validation given by a group of very experienced
well-respected specialists in gastroenterology, surgery
and oncology. The survey instrument presented five dif-
ferent medical situations for which there is no widely
shared consensus.
In the final stage of validation, the questionnaire was
handed to a small pilot group of participants in order to
c o n f i r mt h a tt h eq u e s t i o n s ’ clarity and that the main
idea behind them was well understood.
Following are each of the five specific case-survey
questions and summaries of the answers received in the
survey.
Case number 1
A 71-year old patient presents to you with painless jaun-
dice of 2-3 weeks’ duration. The patient is a nondrinker,
no past hepatitis, CT found a T2N0MO pancreatic head
tumor.Would you recommend:
a- EUS, with FNA of the lesion
b- EUS but NO FNA
Case Number 2
A 68-year old female has a locally advanced T4N0M0
pancreatic tumor as seen on CT scan, inaccessible to
CT-FNA, and considered inoperable due to Superior
Mesenteric Artery encasement or invasion.
Would you recommend:
a- FNA by EUS.
b- Referral to oncotherapy without cytology.
Case Number 3
A 60-year old woman with slight dyspepsia was found to
have external pressure on the stomach during gastro-
scopy. CT found a 30 mm multi-loculated cystic lesion
of the pancreatic body/tail region.
Would you recommend:
a- EUS- FNA.
b- No FNA- refer patient directly to surgery.
Case Number 4
A 55-year old patient has a 2.3 cm pancreatic body cyst
which has not changed since previous CT exam done 6
months ago. The patient feels fine, serum CA19-9, amy-
lase, CEA and CRP all normal.
Would you recommend:
a- EUS-FNA puncture and drainage of the cyst
b- No FNA
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A 50 year old patient examined for heartburn is found
on gastroscopy to have a 19 mm submucosal lesion of
the gastric wall. Before deciding whether to recommend
surgery or long-term follow-up, which would you
recommend:
a- EUS-FNA of the lesion.
b- No FNA
Study Participants
Each case focused on in the survey was handed to physi-
cians (by medical student YR at medical conventions or
on their wards), who were asked to answer it and return it
immediately or send it back by mail. Participants included
specialists and residents from three different specialties
(table 1): gastroenterology (n = 43), surgery (n = 38) and
oncology (n = 20) at four tertiary medical centers and
three smaller hospitals. The physicians were requested, as
part of the survey, to indicate whether or not they person-
ally treat the relevant patients and how many years of
experience they have. Consequently, gastroenterologists
were asked whether they perform EUS themselves, sur-
geons whether they operate on pancreatic lesions them-
selves and oncologists whether they treat patients with
pancreatic lesions and/or GISTs (see tables 2 and 3).
Statistics
As recommended by a statistician, a total number of 150
questionnaires were distributed based on a power study
suggesting that 100 completed surveys would be suffi-
cient to reach statistically significant results from the
intended groups and subgroups. All statistical analyses
were performed by using SPSS software. Reported p
values were all p < 0.05 as levels of significance.
Limitations
In this study, an expert consensus, but not a formal vali-
dation using internal reliability, was obtained. Each med-
ical case presented could have many minor variables
which might change one’s decisions regarding EUS-
guided FNA. However, the thrust of whether or not to
include EUS-guided FNA for the overall situations
seems to have been well served by the questions as were
finally formulated.
Results
In total, 101 physicians answered the survey. The distri-
bution of specialties (see table 1) was 43 gastroenterolo-
gists, 38 surgeons, and 20 oncologists. Furthermore, the
groups were subdivided into two categories: Those who
treat the relevant patients by themselves (e.g. a surgeon
who performs pancreatic operations, a gastroenterologist
w h op e r f o r m sE U S ,e t c . )a n dt h o s ew h od on o t( s e e
table 2). 55% of surgeons, 35% of oncologists, and 16.3%
of gastroenterologists personally treat these patients.
Case number 1
Overall, 68.7% would recommend EUS-FNA of a T2 pan-
creatic head lesion. There were significant differences
between specialties. EUS was considered to be indicated
by51% of surgeons, 74.4% of gastroenterologists and
89.5% of oncologists. The statistical differences between
oncologists and surgeons is p < 0.01; between gastroen-
terologists and surgeons, p < 0.05 (See Figure 1).
Case Number 2
In total, 70.4 percent of the physicians replied that EUS-
guided FNA should be performed in a patient present-
ing with an inoperable pancreatic tumor characterized
to be without metastases according to CT (locally
advanced T4N0M0). The breakdown by specialty, of
those writing that FNA was indicated, was 62% of
Table 1 The Distribution of the Physicians According to
Specialties.





Table 2 The distribution of Those Physicians Who Treat




Oncologists 35% (7) 35% (7) 30% (6) 100% (20)
Gastroenterologists 16.3% (7) 79% (34) 4.7% (2) 100% (43)
Surgeons 55.25%
(21)
34.25% (13) 10.5% (4) 100% (38)
Total 34.6% (35) 53.5% (72) 11.9% (12) 100%
(101)
Numbers in parentheses: case number
Table 3 The distribution of physicians’ experience in
years according to specialty.
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ologists (See Figure 2).
Case Number 3
The overall mean response was that 84% wrote that
FNA is indicated before deciding on surgery for a symp-
tomatic 30 mm multi-loculated cystic lesion of the
pancreatic body/tail region. The group breakdown was
relatively homogeneous: 81.6% surgeons 81.2% of oncol-
ogists and 87.5% of gastroenterologists (See Figure 3).
Case Number 4
In the case of an apparently 23 mm stable asymptomatic
pancreatic cyst with normal serum markers, 66.67% of
Figure 1 Case #1: Is FNA recommended for a T2NOMO 2 cm pancreatic lesion?.
Figure 2 Case #2: Is EUS-FNA recommended before referral for oncotherapy for a pancreatic tumor encasing the Superior Mesenteric
Artery?.
Lachter et al. BMC Gastroenterology 2011, 11:117
http://www.biomedcentral.com/1471-230X/11/117
Page 4 of 9physicians support non-invasive management. By speci-
a l t y ,F N Aw a sw r i t t e na si n d i c a t e db y3 1 %o fs u r g e o n s ,
11% of oncologists, and 44.2% of gastroenterologists.
Statistical differences were found between oncologists
and gastroenterologists at p < 0.05 (See Figure 4).
Of those gastroenterologists performing EUS by them-
selves, 71.4 percent (n = 5) opted for EUS-guided FNA
of the lesion, whereas, 61.7 percent (n = 21) of those
who do not perform EUS by themselves, wrote that con-
servative measures are preferable (p = NS).
Case Number 5
More oncologists (90 percent), as opposed to only 63.2
to 68.3 percent of the other groups wrote that cytologi-
cal evaluation by EUS-FNA is indicated for a 19 mm
gastric submucosal lesion prior to deciding on surgery.
The statistical difference between oncologists and sur-
geons is p < 0.05 (See Figure 5).
Discussion
Prudent applications of the many expensive and some-
times time-consuming modalities which may assess pan-
creatic lesions, continues to challenge clinicians. Local
expertise and availability and costs are all parameters
which may impact on decisions for staging before resec-
tions of these lesions.
Worldwide, some medical centers may inform patients
that they had benign not malignant disease (such as
autoimmune or focal pancreatitis) only after undergoing
a futile major operation. In Israel, which has 18 EUS
centers for a population of 7.5 million persons, such
futile surgery is widely considered to be unacceptable.
Conversely, negative FNA could result in delaying sur-
gery for potentially resectable tumors. As demonstrated
in the first case, for T2N0MO pancreatic lesions, in con-
trast to gastroenterologist and oncologist opinions (73.3-
89.5%), only 51.4 percent of surgeons wrote that FNA is
indicated prior to surgery. This is one of the most con-
tentious issues dividing physicians. While a positive
FNA confirms need for surgery, negative FNA does not
necessarily refute the need for surgery. The frequency
which one accepts of finding post-hoc that surgery was
performed only to find a focal pancreatitis of any cause
is at the focus of the debate. In Israel, every effort to
prevent unnecessary surgery generally includes attempt-
ing FNA and having cytological confirmation if possible.
In places where FNA is unavailable, it might seem much
more acceptable to attempt surgery based on imaging
alone. The false positive rate of surgery may be com-
pared to the rate of operating on what turn out to be
“white or non-inflamed appendix”.I ny o u n gm a l e
patients, the negative appendectomy rate should be low,
perhaps under10%; this means that less than 10% of
misdiagnoses proven at surgery are considered an indi-
cation that too many true appendicitis cases are likely
being missed. The morbidity and mortality risks of pan-
creatic surgery are considerably higher than for appen-
dectomy. Also, the urgency for operation of the
pancreas is less than for appendectomy, for which a
delay in hours could prove disastrous. Thus, the reluc-
tance to accept unnecessary operations may arguably be
lower for pancreatic operations, and the thoroughness
Figure 3 Case #3: Would you recommend EUS only or EUS- with FNA for a three-cm pancreatic cyst/cystic lesion?.
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should be maximal.
Most physicians in this survey (68.7%) wrote that it is
recommended to perform EUS-guided FNA to evaluate
an EUS demonstrated pancreatic lesion prior to surgical
intervention. It is interesting to consider why surgeons
support this measure to a lesser extent in comparison to
their peers (only 51.4% of surgeons). The very physicians
most at risk of disappointing patients were found to be
most likely to decide on operations which might be
futile. The threshold of data needed to decide to operate
by surgeons was found to be lower than among others.
Figure 4 Case #4: Would you recommend EUS-FNA for a stable 23 mm pancreatic cyst seen to be stable and asymptomatic for 6
months by repeated CT scans?.
Figure 5 Case #5: For a 19 mm submucosal lesion of the gastric wall - Would you recommend performing EUS-FNA of the lesion or
not?.
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believe that cytology should be attempted prior to com-
mencing chemotherapy in a patient with an inoperable
pancreatic tumor according to CT. Supporting this deci-
sion are two key considerations: 1- that cytological diag-
nosis could determine the specific tumor type and thus
change the proper choice of chemotherapy in 8-10% of
cases which are not primary pancreatic adenocarcino-
mas and 2- to avoid treating with chemotherapy a
benign inflammatory lesion of the pancreas. Once again,
the consideration of how heavy a preponderance of evi-
dence indicates a need for a specific therapy (in this
case chemotherapy) involves the tendency of physicians
to make risky decisions which could potentially be
avoided by cytology. The risk rate of patients receiving
chemotherapy wrongly treated for a benign condition/
misdiagnosis has not been reported specifically for pan-
creatic lesions. The risks of the specific chemotherapy
being offered vs. the difficulties involved in getting cyto-
logical or histological confirmation are part of an equa-
tion involving clinical cultural and legal environments.
The third case reveals that most physicians, regardless
to their specialty, believe that a symptomatic pancreatic
cyst, even if smaller than 30 mm, should be aspirated
rather than referred directly for surgery. Considerations
supporting EUS-FNA include the possibilities raised by
results of testing the cystic fluid for CEA, amylase and
cytologically determining the presence of glycogen-rich
cells- all which would raise the accuracy of evaluating
the risk of malignancy. Pseudocysts and serous cystade-
nomas are cases for which a watch and wait strategy
would dominate, as opposed to premalignant or malig-
nant cysts which indicate need for require surgical
intervention.
In the fourth case described, the majority of physicians
answering the survey indicated that the management of
an asymptomatic and stable pancreatic cyst, smaller
than 30 mm, is to watch and wait, meaning, follow-up
only. Some disagreement was found within the sub-
groups of gastroenterologists. Of those performing EUS
by themselves, most believe that the cyst should be
drained, whereas, most of those who do not perform
EUS by themselves, recommended more conservative
management. This controversy appears to exist between
the ASGE and ACG guidelines. The former, emphasiz-
ing the risk that every cystic lesion of the pancreas,
regardless of its size, may be malignant (or premalig-
nant) recommends diagnostic evaluation and mentions
the clinical useful information added by assessing the
cystic fluid for tumor markers, amylase and lipase. The
latter, however, allows cross sectional imaging follow-up
as long as the lesion is smaller than 5 mm and remains
asymptomatic and not growing. Increasingly, a cyst
which has all of the EUS features of a serous
cystadenoma is considered a low risk lesion, and defer-
ring FNA and making the diagnosis based on EUS ima-
ging alone is considered an option [9,10].
According to this survey most physicians would avoid
the risks of FNA. This approach, compared to endoso-
nographers, may be due to concerns about the risks,
unawareness of the benefits, and/or considerations of
availability and costs of EUS-FNA. The risks of FNA,
have recently been estimated in a large meta-analysis.
Mortality was found to be about 1/5000, while signifi-
cant morbidities including post-FNA pain and post-FNA
pancreatitis were more common, especially among the
prospective studies [11].
As evident by the fifth and final case, approximately
70 percent of physicians wrote that cytological evidence
should be sought for a suspected GIST. Modern immu-
nohistochemistry tests for c-KIT and PDGFRA can diag-
nose GIST. Impacts of FNA in such a situation are that
low-grade small GISTs may require no therapy, whereas
high-grade GISTs respond very well to imatinib treat-
ment. It is crucial to note that there are many other
intramural/submucosal lesions which could be diag-
nosed by EUS- FNA in this situation, some of which
would have therapeutic impact (e.g. carcinoid).
A final caveat is that FNA is far from a perfect diag-
nostic modality. The ability to obtain accurate samples
from EUS-guided FNA varies from 50 to about 90%,
depending on the organ being sampled, the expertise,
and possibly the presence of a cytologist during the pro-
cedure [12]. Even for cases of thyroid nodules, for which
FNA is done from outside of the body, under relatively
direct vision, and being able to regulate all body part
movements which could adversely affect the procedure
and lead to false negative due to sample error there is a
significant (roughly 20%) rate of non-informative cytol-
ogy results [13].
In the case of a pancreatic lesion visualized by CT,
performing EUS-guided FNA prior to surgical or onco-
logical treatment may provide (in 85% of cases) support-
ing cytological evidence. The role of cytology in a case
in which, according to the CT, the pancreatic tumor is
inoperable, (e.g. due to vascular involvement), is to
determine the proper chemotherapy/radiotherapy, espe-
cially for atypical tumors.
The symptoms associated with pancreatic cysts are
hard to establish. A pancreatic cyst in a symptomatic
patient is an indication for cytological evaluation, and/or
for drainage, with different methods being available
depending on cyst etiology, size, and other variables
[14,15]. The search for more dependable cyst fluid bio-
markers than CEA continues: most recently MUC7 was
found to have significant value in determining likelihood
of a need for surgery and malignant potential of cysts
[16].
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presenting with a small and stable cyst, according to
radiography, is widely considered to be sufficient.
A gastric submucosal lesion may be a GIST, a carci-
noid or a benign harmless lesion, and so it should be
aspirated in order to determine its stage and the treat-
ment. EUS-FNA has become an essential tool in the
diagnosis and staging of pancreatic tumors. The major
advantage of EUS-FNA lies in the ability of EUS to
detect an unresectable disease, to prevent unnecessary
surgical exploration and to diagnose small lesions unde-
tectable by other imaging modalities. EUS-FNA can be
both therapeutic and diagnostic. The diagnostic values
o ft h eF N Aa r em a n y-t h e s eh a v es u b j e c t i v ev a l u e .A s
Brugge, and others since, have summarized, “The chief
advantage of EUS-guided FNA is the ability to target,
small, intra-pancreatic masses” [17]. Most recently,
EUS-guided interventions using FNA needles are being
attempted. Novel EUS based techniques are emerging as
reasonably safe minimally invasive alternative to the sur-
gical or radiological approaches [18]. As FNA comes
into increasing utilization, the measurable impacts in
these various real-life situations can be better
established.
Most recently, the European Society for Gastrointest-
inal Endoscopy published its guidelines for EUS-FNA
[19]. These guidelines take into consideration the many
hundreds of developments which have been discovered
and published in the five years since the International
Society of Pancreatologists (ISP) reported their consen-
sus guidelines [20]. The ISP guidelines, as mentioned
above, went largely unnoticed by the majority of endo-
sonographers, at least insofar as reported in a major sur-
v e yb yB u s c a g l i ae ta li n2 0 0 9[ 8 ] .T h ep r e s e n ts t u d y
differs significantly from the ESGE guideline, in that the
ESGE guidelines are written only by endoscopists/gas-
troenterologists, whilst the present work presents the
differences in perspectives of surgeons, oncologists and
gastroenterologists. Bringing the perspectives of the
referring physicians and end-users of the “products” of
EUS-FNA may help elucidate the professional needs of
the multidisciplinary team who treat these patients.
Conclusions
Cooperation between gastroenterologists, surgeons and
oncologists is essential in order to optimize patients’
therapy. This cooperation may lead to better utilization
of the various resources and, with no less importance,
may also prevent unnecessary procedures, inappropriate
administration of chemotherapy and operations and
hospital admission. Physicians may tend to emphasize
different risks and benefits to patients based on personal
experience in different subspecialties of medicine. Thus,
the oncologist may be most wary of giving
chemotherapy without prior establishment of cytological
or histological gold-standard proof of a diagnosis. Sur-
geons may attempt risky operations on patients if they
have maximally solid proof that the operation is indi-
cated. The frequency of surgery for autoimmune pan-
creatitis (mistakenly misdiagnosed as being a tumor) is
not a rare occurrence, and it is one which all involved
physicians aim to minimize. The risks of FNA and the
risk to benefit ratio are two considerations which gastro-
enterologists weigh perhaps most carefully when consid-
ering how diagnosis will impact management.
Collaborative meetings should be held to determine
management. Local availability of expertise and facilities,
and local experience, should help narrow the differences
in expectations amongst the specialists in teams hand-
ling pancreatic tumors and GISTS. This data should
reach not only those specialists surveyed in the present
study which involved oncologists, surgeons and gastro-
enterologists, but also should also be available to the
primary care physicians who should ideally be involved
and coordinate the patients’ care and treatment. Careful
consideration of the needs and concerns of everyone in
the multidisciplinary professional team treating these
patients is emphasized so that we may all best serve the
patients with these lesions.
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